Tee­ter­ing on the brink, Clo­vis aban­dons an ear­ly ap­proval for Rubra­ca

A long suf­fer­ing Clo­vis On­col­o­gy $CLVS has re­turned with an­oth­er set­back to re­port.

The Boul­der-based Clo­vis is us­ing the SEC once again to com­mu­ni­cate with share­hold­ers, say­ing that af­ter a re­view of their over­all sur­vival da­ta from ARIEL4 they’ll be with­draw­ing an FDA ap­proval from 2016 to mar­ket Rubra­ca as a treat­ment for third-line BR­CA-mu­tat­ed ovar­i­an can­cer. The Eu­ro­pean ap­proval is al­so be­ing dis­card­ed. The EMA launched its re­view of that in­di­ca­tion in April.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER